- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:diseases:aging [01.12.2019] – [Read more] sallieq | home:diseases:aging [01.26.2019] – [defunct cells] sallieq | ||
|---|---|---|---|
| Line 32: | Line 32: | ||
| * **Cellular theory** – According to this theory, the normal body has a finite potential to replicate and maintain functional capacity (Hayflick limit). | * **Cellular theory** – According to this theory, the normal body has a finite potential to replicate and maintain functional capacity (Hayflick limit). | ||
| + | ==== Breaking up defunct cells ==== | ||
| + | [[https:// | ||
| + | Senolytics in idiopathic pulmonary fibrosis]] | ||
| + | < | ||
| + | | ||
| + | |||
| + | Our first-in-humans open-label pilot supports study feasibility and provides initial evidence that senolytics may alleviate physical dysfunction in IPF (({{pubmed> | ||
| ===== Diseases of the aging are chronic diseases ===== | ===== Diseases of the aging are chronic diseases ===== | ||
| Line 138: | Line 145: | ||
| ===== Notes and comments ===== | ===== Notes and comments ===== | ||
| + | //Lee// " I am 70 now (not 65) when we started this conversation ...lolDr' | ||
| < | < | ||
home/diseases/aging.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.